60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasis

WASHINGTON – After 60 weeks of continuous therapy with the investigational drug ixekizumab, 722 patients who initially had moderate to severe plaque psoriasis had Psoriasis Area Severity Index (PASI)...

Source: Rheumatology News - March 10, 2016 Category: Rheumatology Source Type: research